financetom
Business
financetom
/
Business
/
Amazon Insider Sold Shares Worth $1,000,160, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Amazon Insider Sold Shares Worth $1,000,160, According to a Recent SEC Filing
May 13, 2024 2:04 PM

04:41 PM EDT, 05/13/2024 (MT Newswires) -- Jonathan Rubinstein, Director, on May 09, 2024, sold 5,264 shares in Amazon ( AMZN ) for $1,000,160. Following the Form 4 filing with the SEC, Rubinstein has control over a total of 104,400 shares of the company, with 104,400 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1018724/000101872424000089/xslF345X03/wk-form4_1715632640.xml

Price: 186.76, Change: +0.19, Percent Change: +0.10

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Form 8.3
Form 8.3
Mar 30, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Computershare Trustees (Jersey) Limited as trustee of the Schroders Employee Benefit Trust (b) Owner or controller of interests and short positions disclosed,...
CoreWeave Insider Sold Shares Worth $7,202,031, According to a Recent SEC Filing
CoreWeave Insider Sold Shares Worth $7,202,031, According to a Recent SEC Filing
Mar 30, 2026
03:36 AM EDT, 03/30/2026 (MT Newswires) -- Michael N Intrator, 10% Owner, Director, Chief Executive Officer and President, on March 25, 2026, sold 82,456 shares in CoreWeave ( CRWV ) for $7,202,031. Following the Form 4 filing with the SEC, Intrator has control over a total of 5,666,501 Class A common shares of the company, with 5,666,501 shares held directly....
Bristol-Myers Squibb's Heart Disease Drug Met Main Goal in Phase 3 Study
Bristol-Myers Squibb's Heart Disease Drug Met Main Goal in Phase 3 Study
Mar 30, 2026
04:03 AM EDT, 03/30/2026 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Sunday that its Phase 3 trial of its experimental drug, Camzyos, met its primary goal in adolescents with symptomatic obstructive hypertrophic cardiomyopathy. The company said the study demonstrated a statistically significant and clinically meaningful reduction in left ventricular outflow tract gradient at 28 weeks compared with placebo....
Palantir Technologies, Stellantis Renew 5-Year Data Software Partnership
Palantir Technologies, Stellantis Renew 5-Year Data Software Partnership
Mar 30, 2026
03:30 AM EDT, 03/30/2026 (MT Newswires) -- Palantir Technologies ( PLTR ) and Stellantis ( STLA ) said Monday they renewed and expanded a data software partnership initially formed in 2016 for an additional 5 years. The automaker will increase its usage of Palantir's ( PLTR ) data management software and begin implementing its artificial intelligence platform in specific business...
Copyright 2023-2026 - www.financetom.com All Rights Reserved